Spain – Immunosuppressive agents – Suministro de medicamentos biológicos con biosimilares, lote 14 Eculizumab (vía parenteral intravenosa) para el Servicio de Farmacia del Hospital Clínico Universitario de Valladolid, basado en Acuerdo Marco 2025/034, de INGESA "Suministro respetuoso con el medio ambiente de medicamentos biológicos con biosimilares"
awardedGerencia de Atención Especializada Hospital Clínico Univ. de Valladolid · 21038800147640
Value
€512k
Published
30 Oct 2026
Deadline
—
Type
award · framework
33652300 · Medical equipment, pharmaceuticals & personal careES418
Description
Suministro de medicamentos biológicos con biosimilares, lote 14 Eculizumab (vía parenteral intravenosa) para el Servicio de Farmacia del Hospital Clínico Universitario de Valladolid, basado en Acuerdo Marco 2025/034, de INGESA (Suministro respetuoso con el medio ambiente de medicamentos biológicos con biosimilares)
Key facts
- Procedure
- open
- Framework agreement
- Yes — a framework or dynamic purchasing system, not a single contract
- Regime
- publicSector
- Contract references
- 4610019162
- Category
- supplies
Awarded suppliers
- SAMSUNG BIOEPIS NL BV · N0271839C · NL
Supplier location as published: Delft (Paises bajos), 2616 LR, NL
What a subscription adds to this notice
- The documents — every attachment, with its text extracted and searchable
- Qualification — the notice scored against your company profile
- Tracking and alerts — a pipeline for your bids, and the matching notices by email
- The API and MCP — the same record in your own tools and your AI assistant
Provenance
- Source
- ted-eu
- Notice id
- 755003-2026
- First seen
- 30 Oct 2026
- Last updated
- 30 Oct 2026
Licence EU reuse — Commission Decision 2011/833/EU ↗
Source: TED — Tenders Electronic Daily (ted.europa.eu), © European Union, reused under Commission Decision 2011/833/EU.
View at source ↗
GET /api/v1/tenders/b275c17f-f341-42dd-a738-bf2ea48f5470The source notice is authoritative — verify deadlines and documents there before bidding.